AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Aura Biosciences to Present at the Cowen 40th Annual Health Care Conference

February 25, 2020 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 25, 2020--

Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Cowen 40 th Annual Health Care Conference on Tuesday, March 3, 2020, at 9:30 a.m. Eastern Time in Boston, MA.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biopharmaceutical company developing a new class of oncology therapies based on a novel tumor targeting technology for initial application in primary tumors such as ocular and bladder cancers with the potential to treat other cancers. The Company’s proprietary technology platform utilizes viral-like particle bioconjugates (VPBs) that have a dual selectivity mechanism with targeted binding to cancer cells, followed by activation using a common laser. These potent cytotoxic therapies result in acute tumor cell necrosis, while sparing surrounding healthy tissue and activating the immune system to generate an anti-tumor response. Aura’s lead product candidate belzupacap serotalocan (AU-011) is currently in Phase 2 development for the treatment of choroidal melanoma, a vision and life-threatening form of eye cancer for which there are currently no approved therapies. In a Phase 1b/2 study, AU-011 demonstrated compelling efficacy, including high rates of tumor control and vision preservation, along with a favorable safety profile, in patients with choroidal melanoma. The development of AU-011 is partially supported by funding awarded under a CRADA from the U.S. National Institutes of Health’s National Cancer Institute. Future pipeline applications for Aura’s technology include choroidal metastases and primary bladder carcinoma. Aura is headquartered in Cambridge, MA. For more information, visit www.aurabiosciences.com or follow us on Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200225005234/en/

CONTACT: Investors and Media:

Joseph Rayne

Argot Partners

617.340.6075 |joseph@argotpartners.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: ONCOLOGY HEALTH RESEARCH SCIENCE PHARMACEUTICAL OPTICAL BIOTECHNOLOGY

SOURCE: Aura Biosciences, Inc.

Copyright Business Wire 2020.

PUB: 02/25/2020 07:00 AM/DISC: 02/25/2020 07:01 AM

http://www.businesswire.com/news/home/20200225005234/en